Morningstar - Zoomlion Heavy Industry Science Technology Co. Ltd. Class H (8CZ) Zoomlionâ€™s Fiscal-Year 2018 in Line; FVE Raised, Shares Remain Overvalued on Long-Term Uncertainties

Report

Morningstar

Ken Foong

EUR 100.00 For Business Accounts Only

Zoomlionâ€™s Fiscal-Year 2018 in Line; FVE Raised, Shares Remain Overvalued on Long-Term Uncertainties

We raise Zoomlionâ€™s fair value estimate to HKD 3.40 (CNY 2.90) from HKD 3.00 (CNY 2.62), following minor adjustments to our valuation model and rolling forward of our estimates. The lower net debt due to stronger-than-expected cash flow generations in 2018, the appreciation of CNY against HKD and slightly higher growth assumptions resulted in the increase of our fair value estimate. Our no-moat and stable moat trend ratings on the firm remains intact.Â
Zoomlion announced full-year 2018 results w...

01/04/2019 14 EN

Underlying

Zoomlion Heavy Industry Science & Technology Co. Ltd. Class H

See profile

CNE100000X85 Berlin Stock Exchange China

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Ken Foong

Other Reports on these Companies

MarketLine

Shanghai Zhenhua Heavy Industries Co Ltd - Strategy, SWOT and Corporate Finance Report

Summary Shanghai Zhenhua Heavy Industries Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Shanghai Zhenhua Heavy Industries Co Ltd (ZPMC), a subsidiary of China Communication Construction Co Ltd, is a manufacturer of heavy-duty equipment and related components. It designs, manufactures, and markets large port loading and unloading systems. The company's p...

EUR 167.07

May 30, 2023 May 30, 2023 1 EN

TheScreener

Thanks to a better fundamental star rating, ZOOMLION HVY IND sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ZOOMLION HVY IND (HK), active in the Commercial Vehicles & Trucks industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 18, 2022, the closing price was HKD 5.55 and its expected value was estimated at HKD 5.27.

Free Trial

January 19, 2022 January 19, 2022 1 EN

Morningstar

Morningstar | Zoomlionâ€™s Prelim 2Q19 Above Expectations; Shares Remain Overvalued on Long-Term Uncertainties

Despite Zoomlionâ€™s stronger than expected preliminary first-half 2019 results, we think the firm remains overvalued, as we expect a gradual slowdown in Chinaâ€™s infrastructure and construction activities in the long run. Zoomlion guided that first-half 2019 net profit is expected to increase by 172%-212% year over year to CNY 2.4 billion to CNY 2.7 billion from CNY 0.86 billion during the same period last year, above our expectations. This implies that for second-quarter 2019, net profit will increase by 187%-249% year over year to CNY 1.4 billion to CNY 1.7 billion from CNY 0.49 billion du...

EUR 850.00

July 15, 2019 July 15, 2019 3 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Zoomlionâ€™s Fiscal-Year 2018 in Line; FVE Raised, Shares Remain Overvalued on Long-Term Uncertainties

Shanghai Zhenhua Heavy Industries Co Ltd - Strategy, SWOT and Corporate Finance Report

Thanks to a better fundamental star rating, ZOOMLION HVY IND sees an upgrade to Neutral

Morningstar | Zoomlionâ€™s Prelim 2Q19 Above Expectations; Shares Remain Overvalued on Long-Term Uncertainties

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe